München, den 03. MIG invests in deep-tech and life-science companies with a focus on early-stage teams with global ambitions. By extending our innovative Retina Navigation platform, our goal is to become the global leader in novel therapeutic solutions for the growing number of people suffering from retina diseases.We are striving to preserve the eyesight of patients with retina disease. BC GmbH is currently in charge of managing six funds with 150mn Euro under management provided by public institutions and private investors. To give you the best possible experience, this site uses cookies.

The MIG fond portfolio is managed by MIG AG. Our German-American team of experts in ophthalmic devices works closely with eye doctors, clinical specialists and partners all over the world to advance the treatment of diabetic retinopathy. Since 2005 MIG has been launching funds and it has invested in over 20 innovative German and German and Austrian companies to date. By continuing to browse the site, you are agreeing to our use of cookies. Based in Munich, MIG Fonds ranks as one of Germany's most energetic venture capital companies. Since 2005 MIG has been launching funds and it has invested in over 20 innovative German and German and Austrian companies to date. The MIG fond portfolio is managed by MIG AG. The MIG Partners are all entrepreneurs, who actively support the development of portfolio companies.

Konux (stylised as KONUX) is an Internet of Things start-up from Munich. Based in Munich, MIG Fonds ranks as one of Germany's most energetic venture capital companies. MIG Fonds offer private investors the change to participate directly in a portfolio of promising technology companies. With a total volume of over 500 million Euros, the funds are marketed exclusively by HMW Innovations AG (www.hmw-innovations.ag) and are primarily directed at private investors. The company's acquisition in January 2015 by France's leading independent brokerage house for mid cap shares, Oddo & Cie, has further enhanced our service portfolio. By extending our innovative Retina Navigation platform, our goal is to become the global leader in novel therapeutic solutions for the growing number of people suffering from retina diseases.We are striving to preserve the eyesight of patients with retina disease. With a total volume of over 500 million Euros, the funds are marketed exclusively by HMW Innovations AG (www.hmw-innovations.ag) and are primarily directed at private investors.

BC GmbH is currently in charge of managing six funds with 150mn Euro under management provided by public institutions and private investors. Several approaches supporting laser therapy using OCT images were pursued and developed. The focus was on diagnosis, treatment planning and the effect assessment of laser treatment. Being a subsidiary of InvestitionsBank des Landes Brandenburg (ILB), and through investment by the tbg Brandenburg (ILB), and through investment by the tbg Technolgie-Beteiligungs-Gesellschaft mbH of KfW Mittelstandsbank, they grant financial support to growth- and innovation-oriented small & medium-sized enterprises with company domicile or commercial unit in Brandenburg during all phases of business development. And it is this unique combination of the two aspects of standard care that points to the company's goal: OD-OS is breaking new ground in integrating both the diagnosis and therapy in one solution utilizing Retina Navigation. Based in Munich, MIG Fonds ranks as one of Germany's most energetic venture capital companies. At the start of 2008, after more than three years of product and technological development at SMI by a team dedicated to Retina Navigation, OD-OS was created with a solid capital base and the focused target of bringing Retina Navigation to the market.OD-OS is an ISO 13485 certified medical device company.To develop innovative therapy solutions with Navilas, OD-OS continues to develop new products and technologies to enhance the treatment of the retina with laser by providing a more quality controlled treatment process, such as better treatment strategies for treatment planning, enhanced treatment evaluation and dosimetry (in the LADOS-Project) and using advanced imaging technologies (in the OCT-Navigation-Project). In particular, the expertise, the analytical tools and the international presence of the ODDO BHF Group sales team will … Founder and CEO of SMI, redefining refractive and cataract laser surgery with tracking and guidanceOD-OS aims to set new standards of care for retina treatment. For further information on MIG fonds, MIG AG and its investment portfolio, please visit:BC GmbH is a management and holding entity of several investment funds. zu erleiden drohen.Insbesondere werden erfolgreich Schadenersatzansprüche aufgrund von Fehlberatung geltend gemacht. MIG funds are conceived and drawn up by HMW Emissionshaus AG. Founder and CEO of SMI, redefining refractive and cataract laser surgery with tracking and guidanceOD-OS aims to set new standards of care for retina treatment. We provide innovative therapy solutions, being the first to introduce Retina Navigation with its unique integration of imaging, planning, treatment, and documentation - utilizing our advanced overlay technology.The name OD-OS was chosen for the company as it is instantly recognizable and easily remembered by anyone who is involved in retina therapy. Since 2005 MIG has been launching funds and it has invested in over 20 innovative German and German and Austrian companies to date.

Furthermore, OD-OS also stands for Ophthalmic Diagnostics - Ophthalmic Surgery. By continuing to browse the site, you are agreeing to our use of cookies.